Aakaar Medical Technologies Limited
Minimum investment
Bidding date
20 Jun - 24 Jun 2025
Price range
—
Minimum quantity
1,600
Minimum investment
₹1,08,800
Issue size
—
IPO doc (link)
RHP docs
Listing exchange
NSE/BSE
Incorporated in 2013, Aakaar Medical Technologies Limited is a prominent player in the aesthetic and cosmetic medical space. The company offers a diverse range of advanced skincare and haircare products, injectable solutions, and medical-grade devices targeted toward dermatologists, plastic surgeons, cosmetologists, and aesthetic physicians.
Aakaar Medical has built a robust distribution network across multiple Indian states, including Delhi, Maharashtra, Karnataka, Tamil Nadu, and West Bengal, supported by a dedicated team of 90+ trained sales and service engineers.
Its product portfolio includes:
Hair Growth Serums, Anti-Hair Loss Solutions
Medifacial Kits
Tattoo Removal and Skin Rejuvenation Devices
Laser Hair Reduction Equipment
Hair Transplant Devices
Injectable and Contouring Products
Urinary Incontinence Devices
The company sources and manufactures products both locally and internationally from countries like South Korea, Italy, Spain, and Austria. With a diversified customer and product base, Aakaar is strategically placed to grow in India’s booming aesthetic medicine market.
Strong Financial Growth: Aakaar Medical Technologies has shown impressive financial performance, with a 33% rise in revenue and 110% growth in profit (PAT) in FY25 compared to FY24.
High Return Ratios: With a RoNW of 33.81% and ROCE of 21.02%, the company reflects efficient capital usage and strong return potential for investors.
Diversified Product Portfolio: The company offers a wide variety of aesthetic medical products and devices, including both locally manufactured and imported items from countries like South Korea and Italy.
Nationwide Distribution Network: Aakaar Medical operates across multiple Indian states, backed by 90+ sales and service engineers, ensuring a strong pan-India presence.
High-Profit Margins: With an EBITDA margin of 15.81%, the company benefits from its premium product positioning and cost-effective distribution model.
Intense Market Competition: The aesthetic and cosmetic medical segment is highly competitive, with both domestic and international brands vying for market share.
Dependency on Specific Professionals: The company’s revenues are largely dependent on dermatologists, aesthetic physicians, and surgeons, which could pose a risk if demand from this segment declines.
Moderate Financial Leverage: The current debt-to-equity ratio stands at 0.98, indicating moderate borrowing that could impact future financial flexibility.
SME Listing Volatility: Being listed on the NSE SME platform, the stock may face liquidity constraints and higher price volatility compared to mainboard listings.
N/A
Active IPOs | |
|---|---|
Company name | Bid starts |
Cmr Green Technologies | 03-06-2026 |
Hexagon Nutrition | 05-06-2026 |
